Immunai and Boehringer partner to identify T-cell targets

Immunai and Boehringer Ingelheim have entered into a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases. The collaboration will see the companies gather and analyse data from many patient samples. Confirmed findings will move to Immunai’s lab, possibly serving as foundations for new Boehringer Ingelheim drug discovery projects. Credit: nitpicker / Shutterstock.com. Immunai and Boehringer Ingelheim have entered a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases. The initial phase of the partnership, valued at up to $15m and running until 2027, may be expanded if scientific milestones are met and both…

Source: Pharmaceutical Technology